Number of events, crude and standardised incidence rates and HR for all cancers other than NMSC and NMSC, in Swedish patients with PsA treated with JAKi
| Cohort | Events | Crude incidence rate per 1000 person-years | Standardised incidence rate per 1000 person-years | Fully adjusted HR* |
| All cancers other than NMSC | ||||
| JAKi | 5 | 8.6 | 7.3 | 1.88 (0.68 to 5.16) |
| Non-TNFi | 2 | 4.8 | – | – |
| TNFi | 73 | 5.8 | 5.8 | 1.0 (Reference) |
| Gen population | 317 | 5.9 | 6.0 | n/a |
| NMSC | ||||
| JAKi | 8 | 13.9 | 11.7 | 2.05 (0.79 to 5.31) |
| Non-TNFi | 2 | 4.8 | – | – |
| TNFi | 73 | 5.8 | 5.8 | 1.0 (Reference) |
| Gen population | 209 | 3.9 | 3.9 | n/a |
Non-TNFI includes rituximab, abatacept and tocilizumab. Estimated from proportional hazards Cox regression models. Standardised incidence rate standardised to the age- and sex distribution in the TNFi cohort. – is displayed when too few events (<5) were observed.
*Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.
JAKi, Janus kinas inhibitor; n/a, not available; NMSC, non-melanoma skin cancer; PsA, psoriatic arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.